Den europeiske union - norsk - EMA (European Medicines Agency)

ceva santé animale - meloksikam - oxicams - dogs; cats; cattle; pigs; horses - dogsalleviation av betennelse og smerter i både akutte og kroniske muskel-og skjelettlidelser. reduksjon av postoperativ smerte og betennelse etter ortopedisk og mykvev kirurgi. catsreduction av post-operative smerter etter ovariohysterectomy og mindre av mykt vev kirurgi. cattlefor bruk i akutt luftveisinfeksjon med passende antibiotikabehandling for å redusere kliniske tegn hos storfe. for bruk i diaré i kombinasjon med oral rehydreringsterapi for å redusere kliniske tegn i kalver på over en uke og unge, ikke-lakterende storfe. for tilleggsbehandling i behandling av akutt mastitt, i kombinasjon med antibiotikabehandling. pigsfor bruk i ikke-smittsomme locomotor lidelser til å redusere symptomer på halthet og betennelser. for tilleggsbehandling i behandling av puerperal septikemi og toksemi (mastitt-metritis-agalactia syndrom) med passende antibiotikabehandling. horsesfor bruk i lindre betennelser og lindring av smerter i både akutte og kroniske muskel-og skjelettlidelser. for lindring av smerte assosiert med hestekolikk.

Den europeiske union - norsk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - meloksikam - anti-inflammatory and anti-rheumatic products, non-steroids - pigs; cattle - novem 5 mg/ml oppløsning til injeksjon for storfe og svin:cattlefor bruk i akutt luftveisinfeksjon med passende antibiotikabehandling for å redusere kliniske tegn hos storfe. for bruk i diaré i kombinasjon med oral rehydreringsterapi for å redusere kliniske tegn i kalver på over en uke og unge, ikke-lakterende storfe. for lindring av postoperativ smerte etter avhorning i kalver. pigsfor bruk i noninfectious locomotor lidelser til å redusere symptomer på halthet og betennelser. for lindring av postoperativ smerte assosiert med mindre mykvevsoperasjon som kastrering. novem 20 mg/ml oppløsning til injeksjon for storfe og svin:cattlefor bruk i akutt luftveisinfeksjon med passende antibiotikabehandling for å redusere kliniske tegn hos storfe. for bruk i diaré i kombinasjon med oral rehydreringsterapi for å redusere kliniske tegn i kalver på over en uke og unge, ikke-lakterende storfe. for tilleggsbehandling i behandling av akutt mastitt, i kombinasjon med antibiotikabehandling. for lindring av postoperativ smerte etter avhorning i kalver. pigsfor bruk i noninfectious locomotor lidelser til å redusere symptomer på halthet og betennelser. for tilleggsbehandling i behandling av puerperal septikemi og toksemi (mastitt-metritis-agalactia syndrom) med passende antibiotikabehandling. novem 40 mg/ml oppløsning til injeksjon for storfe:for bruk i akutt luftveisinfeksjon med passende antibiotikabehandling for å redusere kliniske tegn hos storfe. for bruk i diaré i kombinasjon med oral rehydratiseringsbehandling for å redusere kliniske tegn i kalver på over en uke og unge, ikke-lakterende storfe. for tilleggsbehandling i behandling av akutt mastitt, i kombinasjon med antibiotikabehandling.

Den europeiske union - norsk - EMA (European Medicines Agency)

n.v. organon - desloratadine, pseudophedrine sulfate - rhinitt, allergisk, sesongmessig - nasale preparater - symptomatisk behandling av sesongmessig allergisk rhinitt når det ledsages av nesestopp.

Den europeiske union - norsk - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - lopinavir, ritonavir - hiv-infeksjoner - antivirals for systemic use, protease inhibitors - kaletra er angitt i kombinasjon med andre antiretrovirale legemidler til behandling av hiv-1-infiserte voksne, ungdommer og barn i alderen 14 og eldre. valg av kaletra til å behandle protease inhibitor opplevd hiv-1 infiserte pasienter bør være basert på individuelle viral motstand testing og behandling historie av pasienter.

Den europeiske union - norsk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - stavudin - hiv-infeksjoner - antivirale midler til systemisk bruk - hard capsuleszerit er indisert i kombinasjon med andre antiretroviral legemidler til behandling av hiv-infiserte voksne pasienter og paediatric pasienter (over en alder av tre måneder) bare når andre antiretrovirals kan ikke brukes. varigheten av behandlingen med zerit bør være begrenset til kortest mulig tid. pulver til oral solutionzerit er indisert i kombinasjon med andre antiretroviral legemidler til behandling av hiv-infiserte voksne pasienter og paediatric pasienter (fra fødsel) bare når andre antiretrovirals kan ikke brukes. varigheten av behandlingen med zerit bør være begrenset til kortest mulig tid.

Den europeiske union - norsk - EMA (European Medicines Agency)

roche registration ltd. - nelfinavir - hiv-infeksjoner - antivirale midler til systemisk bruk - viracept er indisert ved antiretroviral kombinationsbehandling av hiv-1-infiserte voksne, ungdom og barn på tre år og eldre. i protease-inhibitor (pi)-erfarne pasienter, valg av nelfinavir bør være basert på individuelle viral motstand testing og behandling historie.

Den europeiske union - norsk - EMA (European Medicines Agency)

stada arzneimittel ag - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiske midler - oyavas in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. oyavas in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. for ytterligere informasjon om human epidermal growth factor receptor 2 (her2) status, se avsnitt 5. oyavas in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with oyavas in combination with capecitabine. for ytterligere informasjon om her2-status, se avsnitt 5. oyavas, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer other than predominantly squamous cell histology. oyavas, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non squamous non small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. oyavas in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. oyavas, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. oyavas, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents. oyavas, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. oyavas, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Norge - norsk - Statens legemiddelverk

effik s.a - norgestimat / etinyløstradiol - tablett - 0.25 mg / 0.035 mg

Den europeiske union - norsk - EMA (European Medicines Agency)

celltrion healthcare hungary kft. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiske midler - vegzelma in combination with fluoropyrimidine based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. vegzelma in combination with paclitaxel is indicated for first line treatment of adult patients with metastatic breast cancer. for ytterligere informasjon om human epidermal growth factor receptor 2 (her2) status, se avsnitt 5. vegzelma in combination with capecitabine is indicated for first line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracycline containing regimens in the adjuvant setting within the last 12 months should be excluded from treatment with vegzelma in combination with capecitabine. for ytterligere informasjon om her2-status, se avsnitt 5. vegzelma, in addition to platinum based chemotherapy, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent non small cell lung cancer (nsclc) other than predominantly squamous cell histology. vegzelma, in combination with erlotinib, is indicated for first line treatment of adult patients with unresectable advanced, metastatic or recurrent nsclc with epidermal growth factor receptor (egfr) activating mutations (see section 5. vegzelma, in combination with interferon alfa 2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. vegzelma, in combination with carboplatin and paclitaxel is indicated for the front line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. vegzelma, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vascular endothelial growth factor (vegf) inhibitors or vegf receptor–targeted agents. vegzelma in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor–targeted agents (see section 5. vegzelma, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5.

Den europeiske union - norsk - EMA (European Medicines Agency)

samsung bioepis nl b.v. - bevacizumab - colorectal neoplasms; breast neoplasms; ovarian neoplasms; fallopian tube neoplasms; peritoneal neoplasms; carcinoma, non-small-cell lung; carcinoma, renal cell; uterine cervical neoplasms - antineoplastiske midler - aybintio in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of adult patients with metastatic carcinoma of the colon or rectum. aybintio in combination with paclitaxel is indicated for first-line treatment of adult patients with metastatic breast cancer. for ytterligere informasjon om human epidermal growth factor receptor 2 (her2) status, se avsnitt 5. 1 of the smpc. aybintio in combination with capecitabine is indicated for first-line treatment of adult patients with metastatic breast cancer in whom treatment with other chemotherapy options including taxanes or anthracyclines is not considered appropriate. patients who have received taxane and anthracyclinecontaining regimens in the adjuvant setting within the last 12 months should be excluded from treatment with aybintio in combination with capecitabine. for ytterligere informasjon om her2-status, se avsnitt 5. 1 of the smpc. aybintio, in addition to platinum-based chemotherapy, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-small cell lung cancer other than predominantly squamous cell histology. aybintio, in combination with erlotinib, is indicated for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with epidermal growth factor receptor (egfr) activating mutations (see section 5. 1 of the smpc). aybintio in combination with interferon alfa-2a is indicated for first line treatment of adult patients with advanced and/or metastatic renal cell cancer. aybintio, in combination with carboplatin and paclitaxel is indicated for the front-line treatment of adult patients with advanced (international federation of gynecology and obstetrics (figo) stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer (see section 5. 1 of the smpc). aybintio, in combination with carboplatin and gemcitabine or in combination with carboplatin and paclitaxel, is indicated for treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents. aybintio, in combination with topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other vegf inhibitors or vegf receptor targeted agents (see section 5. 1 of the smpc). aybintio, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, is indicated for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix (see section 5. 1 of the smpc).